Sheaff Brock Investment Advisors LLC Sells 25,272 Shares of Johnson & Johnson (NYSE:JNJ)

Sheaff Brock Investment Advisors LLC has reduced its ownership in Johnson & Johnson (NYSE:JNJ) by 58.0% during the fourth quarter of 2025, as stated in their recent Form 13F filing with the Securities and Exchange Commission (SEC). Following the sale of 25,272 shares during the quarter, the institutional investor now holds 18,296 shares, valued at approximately $2,646,000 at the end of the reporting period.

Several other institutional investors have also made changes to their positions in Johnson & Johnson recently. IFS Advisors LLC increased its stake by 138.9% in the fourth quarter, owning 172 shares worth $25,000 after acquiring an additional 100 shares. Similarly, Highline Wealth Partners LLC purchased a new stake in Johnson & Johnson worth $31,000 during the third quarter, and RPg Family Wealth Advisory LLC bought shares valued at $35,000 in the same period. Bay Harbor Wealth Management LLC invested $32,000, while Mowery & Schoenfeld Wealth Management LLC expanded its holdings by 58.7% in the third quarter, now owning 246 shares valued at $40,000. Overall, institutional investors own 69.55% of Johnson & Johnson's shares.

Recent Analyst Ratings

Johnson & Johnson has been a focus of many analysts in recent research reports. Morgan Stanley adjusted their price target from $175.00 to $163.00, maintaining an “equal weight” rating on the stock as of January 23rd. Citigroup also lowered their price target from $185.00 to $175.00 while issuing a “buy” rating on December 11th. On the same day, Bank of America revised their target from $160.00 to $159.00, keeping a “neutral” outlook. Stifel Nicolaus set their price target to $155.00 from a previous $170.00, recommending a “hold” rating. Meanwhile, Royal Bank of Canada reaffirmed an “outperform” rating, setting a target price of $181.00. Currently, nine analysts have rated the stock with a hold rating, eight with a buy rating, and two with a strong buy rating. According to MarketBeat, Johnson & Johnson holds an average rating of “Moderate Buy” with an average target price of $170.67.

Stock Performance

On Thursday, shares of Johnson & Johnson opened at $157.93. The company reports a debt-to-equity ratio of 0.43, a quick ratio of 0.86, and a current ratio of 1.11. The stock's 50-day moving average stands at $148.34, with a 200-day average of $155.86. The stock has seen a 52-week low of $140.68 and a high of $168.85, with a market capitalization of $380.23 billion. The price-to-earnings ratio is recorded at 23.75, with a price-to-earnings-growth ratio of 2.50 and a beta of 0.52.

In its latest quarterly earnings report on January 22nd, Johnson & Johnson announced an earnings per share (EPS) of $2.04, surpassing the consensus estimate of $1.99 by $0.05. The company's net margin was 18.20%, and it recorded a return on equity of 34.24%. The revenue for the quarter was reported at $22.52 billion, slightly above the analysts' expectations of $22.44 billion, and showing a 5.3% increase compared to the same quarter last year. Analysts predict the company will post an EPS of 10.58 for the current year.

Dividend Announcement

Recently, Johnson & Johnson declared a quarterly dividend that will be distributed on March 4th. Shareholders on record as of February 18th will receive a dividend of $1.24 per share, which reflects an annualized amount of $4.96 and a dividend yield of 3.14%. The company's current dividend payout ratio is 74.59%.

Insider Trade Activity

In other news, Mark A. Weinberger, a director at Johnson & Johnson, acquired 1,000 shares on December 12th, purchasing them at an average price of $147.22 each, totaling $147,220. Following this transaction, he owns 1,000 shares with a total value of $147,220. This acquisition was disclosed in a filing with the SEC. Meanwhile, EVP Timothy Schmid sold 403 shares on February 18th at an average price of $156.15, generating a total of $62,928.45. Post-sale, he holds 15,098 shares valued at $2,357,552.70. Insider ownership currently stands at 0.16% of the stock.

About Johnson & Johnson

Johnson & Johnson is a holding company that is engaged in research, development, manufacturing, and sales of healthcare products. It operates through two primary segments: Innovative Medicine, which focuses on areas such as immunology, infectious diseases, neuroscience, oncology, and cardiovascular health, and MedTech.

Investment, Shares, Johnson